Re:Thinking with Adam GrantMark Cuban doesn’t believe in following your passions | Re:Thinking with Adam Grant
CHAPTERS
- 0:02 – 2:12
Mark Cuban’s unexpected Wharton hangout (and why he did it)
Adam opens by recalling Mark Cuban’s late-night visit to Wharton’s campus bar and uses it to set a candid tone. Mark’s simple reason—wanting a beer—turns into a quick look at how he stays curious about how people actually behave (like students’ early Facebook use).
- •Adam’s introduction to the show and to Mark Cuban’s public persona
- •The Wharton bar story as a window into Mark’s approachability
- •A small but telling observation: students using Facebook for groups early on
- •Establishing the conversation’s informal, direct style
- 2:12 – 3:44
The origin of Cost Plus Drugs: a cold email and “radical transparency”
Mark explains how Cost Plus Drugs began with an email from Dr. Alex Oshmyansky and quickly expanded from a narrow nonprofit concept to a broader attempt to remake drug pricing. The core design choice becomes radical transparency—showing costs and using a fixed markup to rebuild trust and prove prices can fall dramatically.
- •Cold outreach from Dr. Alex Oshmyansky sparks the idea
- •Shift from compounding scarce drugs to expanding toward all drugs
- •The transparency problem: consumers can’t explain why drugs cost what they do
- •Cost-plus pricing: cost + 15% (plus fees) as a simple, scalable rule
- •Using extreme price hikes (e.g., Shkreli) as proof prices can also drop massively
- 3:44 – 4:47
Launching in a regulated market: why it took three years (and why Mark put his name on it)
Mark details the operational and regulatory hurdles of becoming a legitimate pharmacy supplier, describing it as the hardest part of the build. He also shares why he ultimately branded it “Mark Cuban Cost Plus Drugs” to signal commitment and credibility to manufacturers and distributors.
- •Navigating heavy pharmacy regulation and compliance requirements
- •The difficulty of getting wholesalers/manufacturers to sell to a new entrant
- •First drug and launch milestone (January 19, 2022)
- •Why Mark added his name: trust, commitment, and financial credibility
- •Partner fulfillment model (Truepill) and website integration
- 4:47 – 6:29
Why this isn’t a charity: building a self-sustaining disruptor
Adam highlights real stories of patients finally affording medication, and Mark emphasizes the moral urgency behind the business. He argues the problem can’t rely on donations, and that adaptability and sustainability require a for-profit engine that can evolve with changing drugs and markets.
- •Impact on patients forced to choose between essentials and medication
- •Mark’s view: charity models struggle with scale and consistency
- •Self-sustaining structure to survive industry change (generics, patents, new meds)
- •Skepticism reserved for supplements, not evidence-based drugs
- •Healthcare curiosity as a long-term learning project leading up to Cost Plus
- 6:29 – 8:30
Learning healthcare from first principles: cost drivers, incentives, and system design
Mark describes funding studies and asking basic comparative questions (Toronto vs. Manhattan) to uncover why costs diverge. The discussion surfaces structural drivers—malpractice, facility design, profitability incentives—and sets up how these incentives shape pricing and behavior.
- •Starting point: ACA uncertainty sparks Mark’s deeper healthcare investigation
- •Comparing costs across cities to identify system-level drivers
- •Key cost drivers: malpractice, private rooms, complex expansion, specialty profit motives
- •Understanding incentives as the gateway to disruption
- •Timing: prior research made Oshmyansky’s pitch the “perfect” moment
- 8:30 – 11:05
The business model reality check: volume, thin margins, and the ‘moat’ question
Adam presses on whether cost-plus can endure without an obvious tech moat, and Mark acknowledges the margin constraints and capital needs. Mark reframes defensibility around trust and word-of-mouth network effects inside disease communities, where savings propagate quickly through support groups.
- •Thin-margin economics: “make it up with volume” and upfront capital burn
- •Benchmarks and projections—even if imperfect—used to set viability thresholds
- •Competitive threat: others could undercut the markup percentage
- •Network effects via patient communities and support groups spreading the word
- •Trust as the core differentiator when the product is literally life-critical
- 11:05 – 14:29
Why Cost Plus avoids marketing: trust, privacy trade-offs, and social proof
Mark argues they don’t need advertising because network effects do the work, but Adam raises the tension between sharing performance info and regulatory limits. The conversation turns to privacy risks in healthcare data and the psychology of social proof—patients and doctors rely on trusted signals under uncertainty.
- •Decision not to advertise; reliance on community-driven growth
- •Insulin as a potential tipping-point product for massive trust amplification
- •Regulatory constraints and why privacy can block beneficial disclosure
- •Risk of reverse-engineering identities from small populations or location data
- •Social proof dynamics: patients follow similar others; doctors also operate under uncertainty
- 14:29 – 17:37
Building a ‘Southwest Airlines’ pharmacy: mission clarity vs. bells and whistles
Mark explains their deliberately narrow mission: be the lowest-cost provider for every medication they can legally sell. That means resisting feature creep (telehealth, content, high-touch service) because even small upgrades can break the margin model at scale.
- •Mark as a customer: personal example of large price drop on a thyroid drug
- •Continuous UX feedback, but with strict cost-benefit discipline
- •Refusing add-ons (telehealth, blogs, concierge service) to protect affordability
- •Operational trade-offs: slower calls, more email/chatbots, fewer service luxuries
- •Positioning: “well-run dollar store for medications” / “Southwest Airlines” analogy
- 17:37 – 23:08
Transparency as a broader strategy: internal trust, Gen Z ‘free agency,’ and crisis reputations
The conversation expands from drug pricing to how transparency can shape employee trust and organizational productivity. Mark argues modern workers see themselves as free agents, and that how leaders behave in crises permanently defines brand reputation for customers and future talent.
- •Radical transparency as a competitive advantage in opaque pricing environments
- •Internal transparency reduces ambiguity and can boost productivity
- •Employees as free agents: firms must re-earn commitment daily
- •Crisis behavior becomes enduring brand memory in the social media era
- •Downsizing critique: long-run damage to innovation, morale, and talent retention
- 23:08 – 26:26
Incentives, capitalism, and why leaders fixate on short-term money
Mark reflects on how his younger self chased wealth and how that shaped decision-making, then contrasts it with his current marginal utility of money. He frames capitalism as freedom to pursue desired outcomes (including impact), while warning that misaligned incentives drive distortions in healthcare and beyond.
- •Personal evolution: from ‘get rich by 35’ to impact-driven decision-making
- •Why few compete the way Cost Plus does: easier to build wealth within the system
- •Hospital and insurer incentives: revenue loops and misaligned patient-cost trade-offs
- •Capitalism as choice of outcomes—not only maximizing profit
- •Generational shift: stronger expectations for mission, well-being, and accountability
- 26:26 – 28:27
Who’s really driving drug price pain: PBMs, payers, and the next move into brand-name drugs
Adam relays pharma CEOs’ defense of margins for R&D, and Mark responds that manufacturers often aren’t the main source of opacity. He points to pharmacy benefit managers and vertically integrated payers as key distortion creators, and explains how Cost Plus transparency can reassign blame and potentially expand volume for manufacturers.
- •Pharma CEO argument: margins fund R&D and global access
- •Mark’s counter: PBMs and payer-owned verticals often create pricing games
- •Transparency can reveal who benefits from distortions
- •Moving beyond generics toward negotiating with brand-name manufacturers
- •Scale benefits: potentially higher manufacturer revenue via increased volume
- 28:27 – 29:24
‘Should medicine be free?’ Efficiency, government roles, and political constraints
Mark rejects the framing of ‘free’ and re-centers the issue on who pays and whether systems are efficient. He’s open to government manufacturing/distribution if it’s more efficient, but skeptical that political incentives and a duopoly structure can execute well.
- •Nothing is truly free; costs shift to taxes, ads, or other payers
- •Pro-government involvement when it improves efficiency and outcomes
- •Example: government producing generics if it reduces Medicare spend
- •Core concern: governance quality and incentive structures
- •Efficiency as the deciding metric, not ideology
- 29:24 – 36:58
The future of work and super teams—plus NBA culture, chemistry, and attention traps
Adam and Mark explore a project-based labor future and whether teams-for-hire can scale, with Mark flagging sales friction and cultural fragility. The discussion pivots to NBA dynamics: managing personalities, defining roles, handling toxicity, and the real-time impact of social media on performance.
- •Work as time arbitrage: trading skills for flexibility and fulfillment
- •Group-based hiring (‘super teams’) benefits and the hardest parts: selling and culture
- •NBA lessons: ‘one knucklehead’ rule; chemistry and role clarity drive performance
- •Leadership and communication: Jason Kidd vs. prior fit for current roster needs
- •Halftime phone checks and social media feedback loops affecting focus and play
- 36:58 – 44:42
Rapid-fire: Luka GOAT odds, rule changes, startup regrets, Shark Tank tactics, and ‘follow your effort’
The closing stretch jumps across sports, investing, and career advice: Mark’s confidence in Luka, his take on three-point evolution and endgame fouls, and his biggest missed investment (Uber). It ends with behind-the-scenes Shark Tank realities and Mark’s signature contrarian advice—don’t follow passion; follow effort.
- •Luka’s GOAT potential (health as the caveat)
- •Why a four-point line would distort the game; defenses will adapt
- •Endgame fouls and free throws as ‘drama’ rather than a problem needing major rule changes
- •Biggest missed investment: Uber, and Mark’s concerns about subsidy-heavy growth
- •Shark Tank: ‘exploding offers’ as TV drama and competitive shtick; pitch timing secrets
- •Career advice: ‘follow your effort, not your passions’ and focus on cash flow/gross margin
